Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Authors: Anas Gazzah, Philippe L. Bédard, Cinta Hierro, Yubin Kang, Albiruni Abdul Razak, M.H. Ryu, B. Demers, Nathalie Fagniez, Christophe Henry, Marie Hospitel, J.C. Soria, Josep Tabernero - Annals of Oncology 2022 cited by 81